Health startup finalist for UAE award

Brazilian health startup Huna has been named a finalist in the Future Health Challenge, an Abu Dhabi initiative run in partnership with MIT Solve, and will compete for the US$200,000 top prize at a pitching session on May 19 during the World Health Assembly in Geneva. Huna — which applies artificial intelligence to routine blood-test data for early cancer detection — was selected from a global pool of 393 institutions spanning 68 countries.

"Building anticipatory health systems through population-level detection," the challenge theme announced by the Future Challenge this year, centers on technologies and approaches that enable earlier detection of health issues across whole populations, according to the United Arab Emirates news agency WAM.

Huna will face finalists from Japan, Australia, the United States and Colombia for the main award. The programme will award US$200,000 to the winner and US$50,000 each to two runners-up. The finalists were publicly announced on Tuesday, April 7, in a dispatch published by Brazilian news outlet ANBA and credited to Da Redação.

Selection and scope

• Applications: 393 institutions from 68 countries applied to the Future Health Challenge.
• Finalists: Huna (Brazil) plus organisations from Japan, Australia, the United States and Colombia.
• Presentation: Finalists will present at the World Health Assembly in Geneva on May 19.
• Prizes: US$200,000 for the winner; US$50,000 each for two runners-up.

Huna’s technology leverages machine learning models to analyze standard blood-test results with the goal of identifying early signals of cancer, a capability that aligns directly with this year’s emphasis on population-level detection and anticipatory health systems. The company’s selection highlights growing interest from global health accelerators and prize programmes in solutions that use existing clinical data to expand screening reach without requiring new, large-scale infrastructure.

According to the ANBA report, semifinalists and organisations that received honorable mentions from countries including Nepal, South Africa, the United Arab Emirates and India will be invited to the Abu Dhabi Future Health Summit in October. There, they will have opportunities to connect with companies and investors who may support further development or scaling.

Outlook

For Huna, the Geneva presentation offers both visibility to health sector decision-makers and concrete financial incentives: the US$200,000 top prize could accelerate product validation, regulatory work or pilot deployments, while the runners-up awards of US$50,000 each provide additional support to other promising entrants. Success in the Future Health Challenge would place Huna alongside a small group of international innovators showcased by Future Challenge and MIT Solve, potentially opening doors to partnerships and investor interest in markets across the Middle East, Europe and Latin America.

The Future Health Challenge’s emphasis on anticipatory systems underscores a broader shift in global health funding toward early-detection tools and population-level analytics — areas where Huna’s blood-test AI approach directly applies. Final judging and prize allocations will be determined following the May 19 presentations in Geneva.